EN DE
Watch Mentice AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mentice AB (MNTC) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Mentice AB stock SEK 13.56, price SEK 15.40, that is 11.9% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0012673291

MA Mentice AB logo Thin data Nov 10, 2026

Mentice AB

MNTC · ST
Expensive, weak quality

Our calculation puts a fair price 12% below what the stock costs today.

Revenue last quarter +26% vs. a year ago.
Expensive Growth (revenue 5y +15.2 %/yr in SEK)
Fair value kr 13.56 · Overvalued
Quality 36/100
Loss-making · -1.5% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Mentice AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 184.50 kr 9.00 Fair Value kr 13.56 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 9.00 – kr 184.50 · fair‑value band kr 10.17 – kr 16.95 · the kr 15.40 price screens above the kr 13.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Mentice in your weekly email

Every Wednesday you see whether Mentice is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology.

Show moreShow less

It operates through the Mentice VIST, Physical Sim, and Ankyras segments.

The company offers virtual simulation products, including VR simulator platforms; procedural learning models; peripheral vascular; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as the VIST virtual patient and Laerdal SimMan vascular medical simulator.

It also provides flow model products, which include physiological flow systems, extensions and add-ons, silicone and 3D printed vessels, and flow system accessories; Ankyras, a clinical decision application; Mentice Live, a cloud-based learning center for medical technology industry and healthcare providers; Right Heart Cath app, a mobile solution for interactive real-time exploration into the right heart catheterization procedure; Vascular Twin, an anatomical replication for procedural and device adoption; research and development services; and professional support services for installation, training, and warranty services.

It operates in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. Mentice AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.

Stock analysis

Mentice AB (MNTC) currently trades at kr 15.40, while our estimate is kr 13.56, 12% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 10.17 (bear) to kr 16.95 (bull), the price of kr 15.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Mentice AB reported revenue of 279M SEK in FY2025 versus 185M SEK in FY2021, a compound +10.8%/yr. Reported net income was −32.3M SEK in FY2025.

Key figures

Market cap 433M SEK (≈ $43.9M) Micro · P/S ratio 1.44 · EPS (TTM) kr −0.1700 · Net margin −1.5% · Return on equity −4.2% · Return on assets (EBIT) −5.7% (5-year average) · Operating margin −3.9% · Revenue (TTM) 303M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −12%, MNTC screens richer than that median.

Fair Value

Bear kr 10.17 Fair Value kr 13.56 Bull kr 16.95
Price kr 15.40 · Downside -11.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 11
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 57
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 66
How calm the share price moves, does not count
Price momentum 71
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 86
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−23.0% (2020) → −11.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MNTC screens overvalued: fair value 12% below the price. Compare with Abbott Laboratories, →

Compare Mentice AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −11.9% · Above median
Profitability
Return on assets −10.4% · Below median
Net margin (12 months) −1.5% · Below median
Operating margin (12 months) −3.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 25.5% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.13× · Pricier than median
P/S (12 months) 1.43× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)17 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs MNTC
Stryker Corporation SYK $325.73 $358.46 +10% vs MNTC
Boston Scientific Corporation BSX $44.02 $48.42 +10% vs MNTC
DexCom, Inc DXCM $81.07 $89.18 +10% vs MNTC
STERIS plc STE $256.94 $279.53 +9% vs MNTC
GE HealthCare Technologies Inc GEHC $84.03 $69.92 −17% vs MNTC
Edwards Lifesciences Corporation EW $104.71 $81.94 −22% vs MNTC
Abbott Laboratories, ABT $110.51 $75.28 −32% vs MNTC
Medtronic plc MDT $102.79 $65.61 −36% vs MNTC
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs MNTC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mentice AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mentice AB Fair Value". https://www.fairvalue-calculator.com/stock/MNTC

Frequently asked questions

Is Mentice AB (MNTC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 13.56 versus a price of kr 15.40, about 12% lower (overvalued).
What is the fair value of MNTC?
Our estimate for Mentice AB is kr 13.56 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 15.40.
What is the quality score of MNTC?
Mentice AB has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mentice AB (MNTC)?
Our calculated price target is the estimate of kr 13.56 (as of Nov 10, 2026). Cautious scenario kr 10.17, optimistic scenario kr 16.95. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Mentice AB stock forecast for 2026?
Our estimate puts fair value at kr 13.56, about 12% lower versus a price of kr 15.40 (overvalued). Cautious scenario kr 10.17, optimistic scenario kr 16.95. The calculation is refreshed regularly with new filings.
What is the revenue of Mentice AB (MNTC)?
Mentice AB reported trailing-twelve-month revenue of about 303M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Mentice AB (MNTC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mentice AB it is kr 13.56 per share (as of Nov 10, 2026), against a price of kr 15.40.
Is Mentice AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MNTC trades above its calculated fair value: price kr 15.40, fair value kr 13.56, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MNTC?
No. The price is what the market pays today (kr 15.40); the fair value is what the company's own numbers justify (kr 13.56). For Mentice AB the two are kr 1.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mentice AB worth?
The market values Mentice AB at about 433M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 15.40; our models calculate a fair value of kr 13.56 per share.
What do the bullish and bearish scenarios say about MNTC?
Our models span a range for Mentice AB: cautious scenario kr 10.17, base kr 13.56, optimistic kr 16.95 per share (as of Nov 10, 2026, price kr 15.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mentice AB (MNTC)?
Balance-sheet figures for Mentice AB (as of Nov 10, 2026): return on equity −4.2%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is MNTC from its 52-week high?
Mentice AB trades at kr 15.40, about 10% below its 52-week high of kr 17.10 and 26% above the low of kr 12.25 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of kr 13.56 is for.
Which stocks are comparable to Mentice AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mentice AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 15.40, calculated fair value kr 13.56 (−12%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2% above its aggregate fair value. Mentice AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mentice AB (MNTC)?
The closing price on Nov 9, 2026 was kr 15.40. Our estimate is kr 13.56, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mentice AB right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Mentice AB

How large is the market capitalisation of Mentice AB (MNTC)?
The market capitalisation of Mentice AB is 433M SEK (≈ $43.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mentice AB (MNTC)?
The price-to-sales ratio of Mentice AB is 1.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mentice AB (MNTC)?
Earnings per share at Mentice AB are kr −0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Mentice AB (MNTC)?
The net margin of Mentice AB is −1.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mentice AB (MNTC)?
The return on equity (ROE) of Mentice AB is −4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mentice AB (MNTC)?
On an EBIT basis the return on assets of Mentice AB is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mentice AB (MNTC)?
The operating margin of Mentice AB is −3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mentice AB (MNTC)?
Revenue at Mentice AB is growing +25.5% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mentice AB (MNTC)?
Earnings per share at Mentice AB are growing +475% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mentice AB (MNTC) generate?
The free cash flow of Mentice AB is −25.4M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Mentice AB (MNTC) hold?
Mentice AB holds more cash than debt, 7.2M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Mentice AB in the live analysis

One click puts Mentice AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.